Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.

Slični predmeti

• Mutational Status of the TP53 Gene as a Predictor of Response and Survival in CLL Patients with and without 17p Deletion
  od: Gonzalez, D, i dr.
  Izdano: (2008)
• A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial.
  od: Dearden, C, i dr.
  Izdano: (2011)
• Prognostic factors in the UK LRF CLL4 trial
  od: Oscier, D, i dr.
  Izdano: (2006)
• Prognostic factors in the UK LRF CLL4 trial.
  od: Oscier, D, i dr.
  Izdano: (2005)
• The combination of fludarabine and cyclophosphamide has a beneficial effect on the incidence of hemolytic anemia in chronic lymphocytic leukemia. Results from the UK LRF CLL4 trial
  od: Dearden, C, i dr.
  Izdano: (2007)